AEON Biopharma Statistics
Total Valuation
AEON Biopharma has a market cap or net worth of $162.01 million. The enterprise value is $156.85 million.
| Market Cap | 162.01M |
| Enterprise Value | 156.85M |
Important Dates
The next estimated earnings date is Saturday, May 11, 2024, before market open.
| Earnings Date | May 11, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
AEON Biopharma has 38.12 million shares outstanding. The number of shares has decreased by -73.24% in one year.
| Shares Outstanding | 38.12M |
| Shares Change (YoY) | -73.24% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 41.19% |
| Owned by Institutions (%) | 22.97% |
| Float | 14.87M |
Valuation Ratios
The trailing PE ratio is 6.54.
| PE Ratio | 6.54 |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 6.52 |
| EV / Sales | n/a |
| EV / EBITDA | 6.51 |
| EV / EBIT | 6.52 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.48
| Current Ratio | 0.48 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -10.90% and return on invested capital (ROIC) is 15.15%.
| Return on Equity (ROE) | -10.90% |
| Return on Assets (ROA) | 272.90% |
| Return on Capital (ROIC) | 15.15% |
| Revenue Per Employee | n/a |
| Profits Per Employee | $2.40M |
| Employee Count | 10 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -58.29% in the last 52 weeks. The beta is 0.41, so AEON Biopharma's price volatility has been lower than the market average.
| Beta (1Y) | 0.41 |
| 52-Week Price Change | -58.29% |
| 50-Day Moving Average | 10.11 |
| 200-Day Moving Average | 7.24 |
| Relative Strength Index (RSI) | 27.70 |
| Average Volume (30 Days) | 63,975 |
Short Selling Information
The latest short interest is 432,840, so 1.14% of the outstanding shares have been sold short.
| Short Interest | 432,840 |
| Short Previous Month | 145,960 |
| Short % of Shares Out | 1.14% |
| Short % of Float | 2.91% |
| Short Ratio (days to cover) | 4.01 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -23.19M |
| Pretax Income | 24.05M |
| Net Income | 24.05M |
| EBITDA | 24.09M |
| EBIT | 24.05M |
| Earnings Per Share (EPS) | $0.65 |
Balance Sheet
The company has $5.16 million in cash and no debt, giving a net cash position of $5.16 million or $0.14 per share.
| Cash & Cash Equivalents | 5.16M |
| Total Debt | n/a |
| Net Cash | 5.16M |
| Net Cash Per Share | $0.14 |
| Equity / Book Value | -153.04M |
| Book Value Per Share | -4.01 |
| Working Capital | -6.83M |
Cash Flow
| Operating Cash Flow | -26.08M |
| Capital Expenditures | n/a |
| Free Cash Flow | -26.08M |
| FCF Per Share | -$0.70 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AEON Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 73.24% |
| Shareholder Yield | 73.24% |
| Earnings Yield | 14.84% |
| FCF Yield | -16.10% |
Analyst Forecast
The average price target for AEON Biopharma is $18.00, which is 323.53% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $18.00 |
| Price Target Difference | 323.53% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | 16.45% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |